stockrow
Saturday 7 November 2026
Export NRIX’s income statement to Excel — free account
Nurix Therapeutics, Inc.
NRIX Healthcare Biotechnology
Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024.
- Revenue
- +8,426.3%
- EPS
- +578.6%
- Free cash flow
- +1,122.1%
Quarter to August 2026, against a year earlier
15.30
0.46
+3.10%
Follow NRIX
Alert me
Nurix Therapeutics, Inc. (NRIX) P/E ratio
As of 6 November 2026, Nurix Therapeutics, Inc. (NRIX) trades at a P/E ratio of 6.1×. Over the past ten years it has ranged from 0.0× (August 2026) to 10.9× (October 2026); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Aug 2026 | 10.3× | — |
| May 2026 | 0.0× | — |
| Feb 2026 | 0.0× | — |
| Nov 2025 | 0.0× | — |
| 24 more quarters | Free account |
Against its own ten years
Low 0.0×
High 10.9×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABSI Absci Corporation compare | n/m |
| SLS SELLAS Life Sciences Group, Inc. compare | n/m |
| GENB Generate Biomedicines, Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| NVAX Novavax, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. | 6.1× |
| BRVE Braveheart Bio, Inc. compare | — |
| LYCA Lycia Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)